“…Following thaw, blastocysts were briefly treated with acidic Tyrode's solution (T1788, Sigma) to remove the zona pellucida and placed in pre-equilibrated human IVC1 in eight-well µ-slide tissue culture plates (80826, Ibidi) in approximately 400 µl volume per embryo per well. Half medium changes were done every 24 h. For small-molecule experiments, human IVC1 was supplemented with either 2 µM A83-01 (72022, STEMCELL Technologies) 80,81 , 25 ng ml −1 Activin-A (Qk001, QKINE) [82][83][84] , 200 nM LDN (S2618, SelleckChem) 85,86 , 50 ng ml −1 BMP6 (SRP3017, Sigma Aldrich) 85,86 , 20 µM DAPT (72082, STEMCELL Technologies) [87][88][89][90] , 10 µM Compound-E (ab142164, Abcam) [91][92][93] , 20 µM MK-0752 (S2660, Selleck Chemicals) [94][95][96] or dimethyl sulfoxide (DMSO) for 48 h. In all cases, these concentrations fall within a range of those used for either vertebrate embryos or complex human ES cell-derived models of the embryo. Within these ranges, a low-to-intermediate concentration was selected to avoid non-specific cytotoxic effects while still considering the higher concentration needed for embryo permeation compared with minimal 2D cell culture to achieve inhibitor action.…”